恶性胶质瘤分子靶向药物联合治疗新动态.pdfVIP

《中国神经肿瘤杂志》2007，5(4)：273-278 273 · 综述· 恶性胶质瘤分子靶向药物联合治疗新动态 杨群英1,2，陈忠平 ， (1．华南肿瘤学国家重点实验室；2．中山大学肿瘤防治中心内科； 3．中山大学肿瘤防治中心神经外科／神经肿瘤科，广东广州 510060) 【摘要】恶性胶质瘤是原发脑肿瘤中最常见的类型，但传统的治疗方法对改善生存作用有限。针对肿瘤细 胞内传导通路上特异分子的靶向治疗是近年的研究热点．但单一分子靶向药物治疗的效果并不十分理想，客 观有效率不超过 10％～15％。因此，人们寄希望于采用联合靶向治疗多个信号传导通路或者同～通路上的不同 靶点和靶向药物与传统的化放疗联合等治疗策略来改善疗效。本文总结近几年来恶性胶质瘤分子靶向药物联 合治疗方面的新动态．其中部分研究已获得令人鼓舞的初步试验数据。 关键词：恶性胶质瘤；分子靶向治疗；化学疗法；放射疗法 中图分类号：R734．41 文献标识码：A 文章编号：1726—8192(2007)04—0273—06 Current Tendency of Combination of Targeted Molecular Therapies for Malignant Gliomas Qun—ying Yang ，-．Zhong—ping Chen ’ ． State Key Laboratory of Oncology in South China,2．Department of Medical Oncology． Cancer Center，Sun Yat—sen University；3．Department of Neurosurgy／Neuro—oncology，Cancer Center,Sun Yat—sen University,Guangzhou，Guangdong,510060， 尺．China 【ABSTRACT]Malignant gliomas are the most common type of primary brain tumom in adult．Despite recent treatment advances in neurosurgery，radiotherapy and chemotherapy，the prognosis of malignant gliomas is still dismal、 Recently， a field under intense investigation is the use of small molecules targeting signaling pathways in~ioma．However，the results of previous clinical trials with sin~e—reagent targeted therapies have only demonstrated a modest survival benefit with a response rate ranging from 10 to 15％、 The combination of different targeted reagents or combination of targeted agents with classical cytotoxic reagents and／or radiotherapy may provide promising new strategies of treatment．In this article，we reviewed current advances in targeted molecular combination therapy for malignant gliomas． KEY WORDS：Gliomas；Targeted